Ovid Therapeutics Inc
OVID
NASDAQ
Biotechnology
$2.83
USD
+0.03 (+1.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $518.86M
Volume 1.2M
Revenue
$1.58M
TTM
-76.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-34.49M
TTM
+9.7%
YoY
Operating Cash Flow
$-54.77M
TTM
-36.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 6.3 | 0.1 | 0.7 | 0.0 | 0.7 |
YoY Growth | +3611.2% | -23.7% | +844.7% | -100.0% | -88.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 6.3 | 0.1 | 0.7 | 0.0 | 0.7 |
Selling, General & Administrative | 4.9 | 6.8 | 6.4 | 6.7 | 6.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 11.3 | 12.7 | 13.0 | 17.8 | 16.4 |
Operating Income | -5.1 | -12.5 | -12.3 | -17.8 | -15.7 |
EBITDA | -5.0 | -12.5 | -12.3 | -17.8 | -15.7 |
Other Income / Expense | 0.4 | 0.4 | 22.0 | 0.9 | 0.7 |
Total Other Income / Expense | 0.4 | 0.4 | 22.0 | 0.9 | 0.7 |
Income Before Income Taxes | -4.7 | -12.2 | 9.7 | -17.0 | -15.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -4.7 | -12.2 | 9.7 | -17.0 | -15.0 |
Consolidated Net Income / Loss | -4.7 | -12.2 | 9.7 | -17.0 | -15.0 |
Net Income Attributable to Common Shareholders | -4.7 | -12.2 | 9.7 | -17.0 | -15.0 |
Basic EPS | -$0.06 | -$0.17 | $0.12 | -$0.12 | -$0.08 |
Diluted EPS | -$0.06 | -$0.17 | $0.12 | -$0.12 | -$0.08 |
Basic Shares Outstanding | 71.1M | 71.1M | 81.7M | 136.2M | 197.5M |
Diluted Shares Outstanding | 71.1M | 71.1M | 81.7M | 136.2M | 197.5M |